NCT07478198

Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Shanghai Punan Hospital of Pudong New District · Academic / Other
• Sex: All
• Age: 30 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Following weight loss with GLP-1 receptor agonists, facial skin laxity and sagging have become another concern for some patients. The temples, cheeks, tear troughs, jawline, marionette lines, and nasolabial folds are the most common areas of volume loss or wrinkles after semaglutide treatment. Restoring facial volume after discontinuing weight-loss medications poses a challenge, as the sole use of hyaluronic acid or permanent fillers may lead to a significant number of patients requiring corrective treatment for overfilled facial syndrome.Poly-L-lactic acid (PLLA) works by releasing low concentrations of lactic acid to stimulate fibroblast-mediated collagen synthesis. Additionally, macrophages participate in the collagen production process triggered by lactic acid, ultimately improving skin laxity. This study aims to evaluate the safety and efficacy of PLLA injections in addressing facial laxity following GLP-1 analogue therapy.

Conditions

• Facial Skin Laxity

Interventions

Type	Name	Description
DEVICE	PLLA injection	Poly-L-lactic acid (PLLA) lyophilized powder, after reconstitution with normal saline, is injected into the subcutaneous layer of the face. Three treatment sessions delivered at 4-week intervals.

Timeline

• Start date: 2025-07-03
• Primary completion: 2026-08-31
• Completion: 2026-12-31
• First posted: 2026-03-17
• Last updated: 2026-03-17

Locations

1 site across 1 country: China